Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SpareBank 1 Markets in connection with its partnership with Swedbank
Mandate

Vinge advises SpareBank 1 Markets in connection with its partnership with Swedbank

March 04, 2025 M&A Financial Regulatory

The partnership between SpareBank 1 Markets and Swedbank aims to create a leading Nordic investment bank. As part of the transaction, SpareBank 1 Markets will receive Swedbank’s Corporate Finance and DCM High-Yield business in Sweden and establish a branch in Stockholm through which the business operations will be conducted.

Pursuant to the partnership, Swedbank will become part-owner of SpareBank 1 Markets with a 20% stake thereby strengthening the position of both banks in the Nordic market and creating new opportunities for expansion in investment banking.

The transaction is subject to regulatory approvals and customary closing conditions.

Vinge’s team primarily consists of Samra Tesser, Nils Unckel, Anton Sjökvist and Gustav Wahlberg.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025